This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioProcess International US West
Mark Your Calendar for BPI US West 2024!
March 11-14, 2024Town and Country Resort, San Diego

Bijan Boldajipour
Vice President Discovery and Development at Lyell Immunopharma, Inc., USA


Bijan Boldajipour oversees the Discovery and Development Team at Lyell that develops novel chimeric antigen receptor (CAR), TCR and tumor-infiltrating lymphocyte (TIL) products for the treatment of cancer. His team investigates how T cells can be genetically engineered to increase their anti-tumor potential and how to make them resistant to the suppressive tumor microenvironment. He brings 13 years of academic and industry experience, researching mechanisms of T cell dysfunction in tumors at UCSF and developing adoptive T cell therapies at Pfizer and Kite Pharma.

Agenda Sessions

  • Preclinical Development of LYL119, a ROR1-Targeted CAR T-cell Product Incorporating Four Novel T-Cell Reprogramming Technologies to Overcome Barriers to Effective Cell Therapy for Solid